美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Lakewood-Amedex Biotherapeutics (Direct Listing)

2.18

-0.0601-2.68%

成交量：3.40万

成交额：7.41万

市值：516.57万

市盈率：-0.21

高：2.27

开：2.20

低：2.10

收：2.24

52周最高：98.20

52周最低：1.66

股本：236.97万

流通股本：141.56万

量比：0.50

换手率：2.40%

股息：- -

股息率：- -

每股收益(TTM):-10.2000

每股收益(LYR):-8.3987

净资产收益率：-402.84%

总资产收益率：-139.40%

市净率：1.19

市盈率(LYR):-0.26

数据加载中...

总览公司新闻资讯公告

Lakewood-Amedex Biotherapeutics 完成感染性糖尿病足溃疡二期a阶段试验最终筹备

Lakewood-Amedex Biotherapeutics - Nu-3在临床前研究中展现良好耐受性，高剂量下系统暴露量低

Lakewood-Amedex Biotherapeutics公布临床前安全性数据，支持Nu-3凝胶即将开展的2a期试验剂量选择

Lakewood-Amedex Biotherapeutics 准备推进 Nu-3 针对感染性糖尿病足溃疡的二期临床开发

Lakewood-Amedex Biotherapeutics 宣布普通股1比10反向拆股 - 美国证券交易委员会文件

Lakewood-Amedex Biotherapeutics：关键制剂、递送与生产步骤完成，为计划中的二期临床试验做准备

Lakewood-Amedex Biotherapeutics 宣布其领先候选药物 Nu-3 在治疗感染性糖尿病足溃疡方面取得积极数据

Lakewood-Amedex Biotherapeutics 宣布与Peri达成协议，后者将担任Nu-3二期临床试验的合同研究组织

Lakewood-Amedex Biotherapeutics公司Nu-3保持对环丙沙星耐药菌的活性

Lakewood-Amedex Biotherapeutics公布针对感染性糖尿病足溃疡的主要候选药物抗微生物耐药性积极数据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/LABT/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":2.1799,"timestamp":1787599734786,"preClose":2.24,"halted":0,"volume":34031,"delay":0,"changeRate":-0.02683035714285726,"floatShares":1415552,"shares":2369700,"eps":-10.199959,"marketStatus":"交易中","change":-0.0601,"latestTime":"08-24 15:29:28 EDT","open":2.2,"high":2.2722,"low":2.1,"amount":74059.8004012,"amplitude":0.076875,"askPrice":2.18,"askSize":260,"bidPrice":2.12,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-10.199959,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":2.24,"preHourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.24,"latestTime":"09:28 EDT","volume":1059,"amount":2400.443772,"timestamp":1787578082120,"change":-0.04,"changeRate":-0.017857,"amplitude":0.093616},"postHourTrading":{"tag":"盘后","latestPrice":2.18,"preClose":2.24,"latestTime":"19:12 EDT","volume":4097,"amount":9153.5807,"timestamp":1787353959572,"change":-0.06,"changeRate":-0.026786,"amplitude":0.03125},"volumeRatio":0.496538},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":1415552,"roa":"-139.40%","roe":"-402.84%","lyrEps":-8.39872,"volumeRatio":0.496538,"shares":2369700,"dividePrice":0,"high":2.2722,"amplitude":0.076875,"preClose":2.24,"low":2.1,"week52Low":1.66,"pbRate":"1.19","week52High":98.2,"institutionHeld":0,"latestPrice":2.1799,"committee":-0.992337,"eps":-10.199959,"divideRate":0,"volume":34031,"delay":0,"ttmEps":-10.199959,"open":2.2,"prevYearClose":80,"prevWeekClose":2.24,"prevMonthClose":2.02,"prevQuarterClose":3.14,"fiveDayClose":2.16,"twentyDayClose":2.5,"sixtyDayClose":7.299},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-08-21","current":-0.219609,"percent":0.905405,"low":-12.282138,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"high":-0.62611,"avg":-2.731171,"sd":3.316371,"marketCap":5189616},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-18","current":-2.241304,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"marketCap":8623724},{"date":"2026-06-26","current":-1.276597,"twenty":-10.242559,"median":-2.72924,"eighty":-2.388094,"marketCap":4911883},{"date":"2026-07-02","current":-1.116845,"twenty":-7.294845,"median":-2.69016,"eighty":-1.477578,"marketCap":4725718},{"date":"2026-07-10","current":-0.893476,"twenty":-5.58279,"median":-2.580737,"eighty":-1.276597,"marketCap":3780575},{"date":"2026-07-17","current":-0.62611,"twenty":-3.536511,"median":-2.512255,"eighty":-1.062695,"marketCap":2649266},{"date":"2026-07-24","current":-1.03562,"twenty":-3.225364,"median":-2.41344,"eighty":-0.92732,"marketCap":4382030},{"date":"2026-07-31","current":-0.653185,"twenty":-2.937143,"median":-2.34533,"eighty":-0.879262,"marketCap":2763829},{"date":"2026-08-07","current":-0.754716,"twenty":-2.857942,"median":-1.477578,"eighty":-0.80819,"marketCap":3193440},{"date":"2026-08-14","current":-0.78856,"twenty":-2.830251,"median":-1.371504,"eighty":-0.793975,"marketCap":3336643},{"date":"2026-08-21","current":-0.706322,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"marketCap":5189616}],"updateTime":1787565013359},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABT\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1105205621","title":"Lakewood-Amedex Biotherapeutics 完成感染性糖尿病足溃疡二期a阶段试验最终筹备","url":"https://stock-news.laohu8.com/highlight/detail?id=1105205621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105205621?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 20:04","pubTimestamp":1784117062,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已进入其针对感染性糖尿病足溃疡治疗的二期a阶段临床试验的最终准备阶段。公司正集中资源推进试验流程，标志着其核心疗法开发进入关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146064134","title":"Lakewood-Amedex Biotherapeutics - Nu-3在临床前研究中展现良好耐受性，高剂量下系统暴露量低","url":"https://stock-news.laohu8.com/highlight/detail?id=1146064134","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146064134?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 20:03","pubTimestamp":1784117015,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics（直接上市）宣布，其候选药物Nu-3在近期完成的临床前研究中取得了积极结果。数据显示，即使在较高剂量下，Nu-3也表现出良好的耐受性，且系统暴露水平维持在较低范围。这一发现为该药物的进一步开发提供了重要的安全性依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125245294","title":"Lakewood-Amedex Biotherapeutics公布临床前安全性数据，支持Nu-3凝胶即将开展的2a期试验剂量选择","url":"https://stock-news.laohu8.com/highlight/detail?id=1125245294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125245294?lang=zh_cn&edition=fundamental","pubTime":"2026-07-15 20:03","pubTimestamp":1784116990,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司宣布了其Nu-3凝胶的临床前安全性数据。这些关键数据为即将启动的2a期临床试验中的临床剂量选择提供了有力支持。研究结果表明，Nu-3凝胶在所测试的剂量范围内展现出良好的安全性特征，这为后续临床研究的顺利推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150730441","title":"Lakewood-Amedex Biotherapeutics 准备推进 Nu-3 针对感染性糖尿病足溃疡的二期临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1150730441","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150730441?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 20:08","pubTimestamp":1783426135,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 正准备将其候选药物 Nu-3 推进至二期临床开发阶段，该药物旨在治疗感染性糖尿病足溃疡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155453862","title":"Lakewood-Amedex Biotherapeutics 宣布普通股1比10反向拆股 - 美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1155453862","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155453862?lang=zh_cn&edition=fundamental","pubTime":"2026-06-17 23:42","pubTimestamp":1781710936,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已向美国证券交易委员会提交文件，宣布对其已发行的普通股进行一比十的反向股票分割。\n此项公司行动旨在调整其股本结构。反向拆股预计将于近期生效，具体细节请参阅公司提交的正式监管文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187732926","title":"Lakewood-Amedex Biotherapeutics：关键制剂、递送与生产步骤完成，为计划中的二期临床试验做准备","url":"https://stock-news.laohu8.com/highlight/detail?id=1187732926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187732926?lang=zh_cn&edition=fundamental","pubTime":"2026-05-18 20:06","pubTimestamp":1779105973,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 宣布，已成功完成关键制剂、药物递送及生产工艺步骤，为其计划开展的二期临床试验做好了充分准备。这些进展标志着公司在推进其候选疗法方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165537088","title":"Lakewood-Amedex Biotherapeutics 宣布其领先候选药物 Nu-3 在治疗感染性糖尿病足溃疡方面取得积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1165537088","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165537088?lang=zh_cn&edition=fundamental","pubTime":"2026-05-18 20:03","pubTimestamp":1779105797,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 公布了其领先候选药物 Nu-3 在治疗感染性糖尿病足溃疡方面取得积极数据，这标志着该药物研发进程的又一重要进展。这些数据为 Nu-3 的进一步临床开发提供了有力支持，有望为这一难治性感染领域带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184734412","title":"Lakewood-Amedex Biotherapeutics 宣布与Peri达成协议，后者将担任Nu-3二期临床试验的合同研究组织","url":"https://stock-news.laohu8.com/highlight/detail?id=1184734412","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184734412?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 20:03","pubTimestamp":1778587406,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已正式宣布与Peri公司达成一项合作协议。根据协议条款，Peri公司将作为合同研究组织，负责其候选药物Nu-3的二期临床试验工作。此举标志着该药物研发进程迈入了新的关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159948293","title":"Lakewood-Amedex Biotherapeutics公司Nu-3保持对环丙沙星耐药菌的活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159948293","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159948293?lang=zh_cn&edition=fundamental","pubTime":"2026-05-01 20:04","pubTimestamp":1777637062,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司宣布，其创新抗菌药物Nu-3在最新实验研究中展现出持续对抗环丙沙星耐药菌的显著活性。这一突破性发现为应对日益严峻的抗生素耐药性问题提供了新的解决方案。\n研究数据表明，Nu-3不仅能有效抑制对环丙沙星产生耐药性的菌株，其抗菌机制还展现出与传统抗生素不同的作用路径。这种独特的分子结构设计使其能够规避细菌常见的耐药机制，为开发新一代抗菌疗法开辟了前景。\n该成果对公共卫生领域具有重要意义，特别是在治疗多重耐药菌感染方面显示出潜在临床应用价值。公司将继续推进相关研究，进一步验证Nu-3在更广泛病原体中的抗菌效能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161086272","title":"Lakewood-Amedex Biotherapeutics公布针对感染性糖尿病足溃疡的主要候选药物抗微生物耐药性积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1161086272","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161086272?lang=zh_cn&edition=fundamental","pubTime":"2026-05-01 20:04","pubTimestamp":1777637056,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司近日披露了其针对感染性糖尿病足溃疡的主要候选药物在抗微生物耐药性方面取得的积极研究数据。这项进展标志着该公司在开发新型抗菌疗法领域迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}